These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 26344809)

  • 1. Control treatments in biologics trials of rheumatoid arthritis were often not deemed acceptable in the context of care.
    Estellat C; Tubach F; Seror R; Alfaiate T; Hajage D; De Rycke Y; Ravaud P
    J Clin Epidemiol; 2016 Jan; 69():235-44. PubMed ID: 26344809
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Randomized controlled trials of rheumatoid arthritis registered at ClinicalTrials.gov: what gets published and when.
    Khan NA; Singh M; Spencer HJ; Torralba KD
    Arthritis Rheumatol; 2014 Oct; 66(10):2664-74. PubMed ID: 25154608
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effectiveness of tumor necrosis factor inhibitors in rheumatoid arthritis in an observational cohort study: comparison of patients according to their eligibility for major randomized clinical trials.
    Zink A; Strangfeld A; Schneider M; Herzer P; Hierse F; Stoyanova-Scholz M; Wassenberg S; Kapelle A; Listing J
    Arthritis Rheum; 2006 Nov; 54(11):3399-407. PubMed ID: 17075823
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A comparison of rheumatoid arthritis and systemic lupus erythematosus trial design: a commentary on ways to improve the number of positive trials in SLE.
    Miles A; Pope JE
    Clin Exp Rheumatol; 2015; 33(5):671-80. PubMed ID: 26315693
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Generalizability of Patients With Rheumatoid Arthritis in Biologic Agent Clinical Trials.
    Vashisht P; Sayles H; Cannella AC; Mikuls TR; Michaud K
    Arthritis Care Res (Hoboken); 2016 Oct; 68(10):1478-88. PubMed ID: 26866293
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical data gap between phase III clinical trials (pre-marketing) and phase IV (post-marketing) studies: evaluation of etanercept in rheumatoid arthritis.
    Farahani P; Levine M; Gaebel K; Thabane L
    Can J Clin Pharmacol; 2005; 12(3):e254-63. PubMed ID: 16278497
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment-related improvement in physical function varies with duration of rheumatoid arthritis: a pooled analysis of clinical trial results.
    Aletaha D; Strand V; Smolen JS; Ward MM
    Ann Rheum Dis; 2008 Feb; 67(2):238-43. PubMed ID: 17644550
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Joint damage progression in patients with rheumatoid arthritis in clinical remission: do biologics perform better than synthetic antirheumatic drugs?
    Ciubotariu E; Gabay C; Finckh A;
    J Rheumatol; 2014 Aug; 41(8):1576-82. PubMed ID: 25028383
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Real-world utilization of DMARDs and biologics in rheumatoid arthritis: the RADIUS (Rheumatoid Arthritis Disease-Modifying Anti-Rheumatic Drug Intervention and Utilization Study) study.
    Gibofsky A; Palmer WR; Goldman JA; Lautzenheiser RL; Markenson JA; Weaver A; Schiff MH; Keystone EC; Paulus HE; Harrison MJ; Whitmore JB; Leff JA
    Curr Med Res Opin; 2006 Jan; 22(1):169-83. PubMed ID: 16393443
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treating rheumatoid arthritis to target: a Canadian patient survey.
    Haraoui B; Bensen W; Thorne C; Wade J; Deamude M; Prince J; Légaré J
    J Clin Rheumatol; 2014 Mar; 20(2):61-7. PubMed ID: 24561407
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Are patients with rheumatoid arthritis still at an increased risk of tuberculosis and what is the role of biological treatments?
    Arkema EV; Jonsson J; Baecklund E; Bruchfeld J; Feltelius N; Askling J;
    Ann Rheum Dis; 2015 Jun; 74(6):1212-7. PubMed ID: 24608401
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Review of head-to-head study designs in rheumatoid arthritis.
    R F; R L; J S S
    Semin Arthritis Rheum; 2016 Dec; 46(3):279-285. PubMed ID: 27692967
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Individual variations in treatment decisions by Swedish rheumatologists regarding biological drugs for rheumatoid arthritis.
    Kalkan A; Hallert E; Carlsson P; Roback K; Sjöwall C
    Scand J Rheumatol; 2015; 44(4):265-70. PubMed ID: 26202443
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dose de-escalation strategies and role of therapeutic drug monitoring of biologics in RA.
    den Broeder AA; van der Maas A; van den Bemt BJ
    Rheumatology (Oxford); 2010 Oct; 49(10):1801-3. PubMed ID: 20332095
    [No Abstract]   [Full Text] [Related]  

  • 15. Factors associated with patients' loss to follow-up after finishing randomized clinical trial participation.
    Strusberg I; Bertoli AM; Ramos M; Fierro G; Pizzolato R; Exeni I; Strusberg AM
    Contemp Clin Trials; 2005 Feb; 26(1):38-44. PubMed ID: 15837451
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lack of head-to-head trials and fair control arms: randomized controlled trials of biologic treatment for rheumatoid arthritis.
    Estellat C; Ravaud P
    Arch Intern Med; 2012 Feb; 172(3):237-44. PubMed ID: 22332155
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Are sample sizes of randomized clinical trials in rheumatoid arthritis too large?
    Celik S; Yazici Y; Yazici H
    Eur J Clin Invest; 2014 Nov; 44(11):1034-44. PubMed ID: 25207845
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Unbalanced rather than balanced randomized controlled trials are more often positive in favor of the new treatment: an exposed and nonexposed study.
    Dibao-Dina C; Caille A; Giraudeau B
    J Clin Epidemiol; 2015 Aug; 68(8):944-9. PubMed ID: 25892193
    [TBL] [Abstract][Full Text] [Related]  

  • 19. What drives the comparative effectiveness of biologics vs. methotrexate in rheumatoid arthritis? Meta-regression and graphical inspection of suspected clinical factors.
    Kanters S; Druyts E; Mills EJ; Thorlund K
    Rheumatology (Oxford); 2014 Jul; 53(7):1264-73. PubMed ID: 24599922
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Real-world effectiveness of select biologic and DMARD monotherapy and combination therapy in the treatment of rheumatoid arthritis: results from the RADIUS observational registry.
    Weaver AL; Lautzenheiser RL; Schiff MH; Gibofsky A; Perruquet JL; Luetkemeyer J; Paulus HE; Xia HA; Leff JA;
    Curr Med Res Opin; 2006 Jan; 22(1):185-98. PubMed ID: 16393444
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.